Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

the Predictors of Different ECASS-based Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients Treated With Alteplase

NCT06653946 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.

NCT NCT06653946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06653946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
the Predictors of Different ECASS-based Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients Treated With Alteplase
Lead sponsor
Kafrelsheikh University
Phase
Phase 4
Overall status
Recruiting
Start date
July 1, 2022
Completion date
November 1, 2024
Enrollment
716 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alteplase adverse reaction, ischemic stroke